🌐 What the Company Does
Amgen (AMGN) is a large global biotechnology company that develops, manufactures, and sells medicines for serious diseases. Its main treatment areas include cancer, inflammation, bone health, cardiovascular disease, and rare diseases.
Unlike smaller biotech companies that may depend on one experimental drug, Amgen has a broad portfolio of approved medicines, global manufacturing capacity, and strong operating cash flow.
Plain English: Amgen is a mature biotech company. It already sells many important medicines worldwide, but it still needs successful new drugs to support future growth.
📊 Financial Highlights
Amgen reported $36.8 billion in total revenue in FY2025, up from $33.4 billion in FY2024. Product sales remained the main revenue driver.
- Revenue: Increased to $36.8 billion in FY2025.
- Operating income: Improved to $9.1 billion.
- Net income: Rebounded to $7.7 billion.
- Diluted EPS: Increased to $14.2.
- Operating cash flow: Remained strong at nearly $10.0 billion.
Profitability improved in FY2025 as revenue grew and cost of sales declined compared with FY2024. Amgen also continued reducing long-term debt, which fell from $56.5 billion in FY2024 to $50.0 billion in FY2025.
Plain English: Amgen grew sales, improved profit margins, generated strong cash flow, and reduced debt during FY2025.
⚠️ Key Risks
Amgen’s most important risks are closely tied to the biotechnology industry. The company depends on successful drug development, patent protection, regulatory approvals, and continued demand for key medicines.
- Patent risk: Older medicines may face biosimilar or generic competition after exclusivity ends.
- Drug development risk: New medicines can fail in clinical trials or regulatory review.
- Pricing pressure: Governments, insurers, and healthcare systems may push for lower drug prices.
- Manufacturing complexity: Biologic medicines are difficult to produce and require strict quality control.
- Debt burden: Amgen still carries a large debt position after past acquisition activity.
Plain English: Amgen is financially strong, but its future still depends on protecting existing products, launching new medicines, and managing debt responsibly.
🧭 MD&A
Management described FY2025 as a year of stronger revenue growth, improved profitability, and continued cash generation. Newer medicines, biosimilars, and acquisition-related products helped support overall performance.
Management also emphasized continued investment in research and development, which is critical for future drug launches and long-term growth in biotechnology.
The company used cash flow for debt repayment, dividends, capital expenditures, and pipeline investment. Management also highlighted ongoing industry challenges, including pricing pressure, competition, regulatory complexity, and patent-related risks.
Plain English: Management’s main message was that Amgen is growing, investing in future medicines, and working to reduce debt while still returning cash to shareholders.
✅ Takeaway
Amgen’s FY2025 10-K shows a large, established biotechnology company with growing revenue, improving profitability, strong cash flow, and a diversified portfolio of approved medicines.
The company is not as speculative as many smaller biotech firms because it already generates substantial revenue and profit. However, investors should still watch patent expirations, drug pricing pressure, biosimilar competition, debt levels, and pipeline execution.
For beginner investors, the key point is simple: Amgen combines mature healthcare cash flow with biotech innovation risk.
Income Statement Summary
| (Unit: $m, EPS in $) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | 28,190 | 33,424 | 36,751 |
| Cost of Goods Sold | 8,451 | 12,858 | 12,037 |
| Gross Profit | 19,739 | 20,566 | 24,714 |
| SG&A | 6,179 | 7,096 | 7,050 |
| Operating Income | 7,897 | 7,258 | 9,080 |
| Non-Operating Income/Expense | 2,833 | 506 | 2,651 |
| Interest Income/Expense | (2,875) | (3,155) | (2,755) |
| Income Before Tax | 7,855 | 4,609 | 8,976 |
| Income Tax | 1,138 | 519 | 1,265 |
| Net Income | 6,717 | 4,090 | 7,711 |
| EPS | 12.5 | 7.6 | 14.2 |
Plain English: Amgen’s revenue increased from $28.2 billion in FY2023 to $36.8 billion in FY2025. The biggest improvement in FY2025 was not just revenue growth, but also better cost control: cost of sales declined from FY2024 even though revenue increased. This helped gross profit and operating income recover strongly. Net income also rebounded to $7.7 billion, and diluted EPS rose to $14.2.
Key Financial Ratios
| Ratio | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| ROE (%) | 107.8% | 69.6% | 89.1% |
| ROA (%) | 6.9% | 4.5% | 8.5% |
| ROTC (%) | 11.1% | 11.0% | 14.4% |
| ROIC (%) | 11.3% | 11.9% | 14.4% |
| Gross Margin (%) | 70.0% | 61.5% | 67.2% |
| Operating Margin (%) | 28.0% | 21.7% | 24.7% |
| Pretax Margin (%) | 27.9% | 13.8% | 24.4% |
| Net Margin (%) | 23.8% | 12.2% | 21.0% |
| Debt-to-Equity Ratio (D/E) (%) | 1,036.8% | 1,022.6% | 630.7% |
| Net Debt / EBITDA (x) | 4.5x | 3.7x | 3.2x |
| Interest Coverage Ratio (x) | 2.7x | 2.3x | 3.3x |
| Current Ratio (%) | 164.9% | 125.7% | 114.0% |
| Quick Ratio (%) | 99.0% | 81.2% | 73.4% |
| Fixed Asset to Long-term Capital Ratio (%) | 8.6% | 10.5% | 13.5% |
Plain English: Amgen’s profitability improved meaningfully in FY2025. Gross margin recovered to 67.2%, operating margin rose to 24.7%, and net margin improved to 21.0%. Leverage remained high, but the direction improved: Debt-to-Equity fell from 1,022.6% in FY2024 to 630.7% in FY2025, and Net Debt / EBITDA improved to 3.2x. This suggests Amgen still carries a large debt load, but its stronger earnings and debt repayment helped reduce leverage pressure.
📝 Disclaimer
This article is intended for educational purposes only. It does not constitute financial, investment, or legal advice. All investment decisions involve risks, and readers should conduct their own research or consult with a licensed financial advisor.
👉 Amgen (AMGN) FY 2025 10-K Analysis (Filed 2026) | Explained for Beginners
Originally published on Finvincio